arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

GeneDx Holdings Corp.

WGS
$64.36 ▼ -5.08 (-7.32%) at close
Healthcare ·Services-Health Services ·USServices-Health Services
8 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
36
Health
Weak
Bearish
auto_awesome

Analytical Summary

GeneDx Holdings Corp. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.8B
Dividend Yield —
Revenue Growth 40.0% ↘
Op. Margin -3.1% ↗
ROIC -3.6% ↗
FCF / Share $0.50 ↗
Trailing P/E —
Price / Book 6.1x
FCF Yield 0.8%
Debt / Equity 0.18
info Valuation on last close. End-of-day price, Nov 5, 2026.

8-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$427.54M
↑ +40.0% —
Net Income Profit after all expenses
$-21.02M
↑ +59.8% —
Operating Margin Operating profit as % of sales
-3.1%
↑ +59.8% 23th
FCF / Share Free cash flow per share
$0.50
↑ +139.4% —
Long-Term Debt Long-term obligations
$54.54M
↑ +5.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
27
Returns ↑
37
Financial Health ↑
58
Cash Quality
12

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 8 years · 27 quarters